-+ 0.00%
-+ 0.00%
-+ 0.00%

Context Therapeutics reports 29% response rate in Phase 1 trial of CTIM-76 for platinum-resistant ovarian cancer

PUBT·06/15/2026 10:30:33
Listen to the news
Context Therapeutics reports 29% response rate in Phase 1 trial of CTIM-76 for platinum-resistant ovarian cancer
  • Context Therapeutics reported positive interim Phase 1 results for CTIM-76 in late-line platinum-resistant ovarian cancer; results have now been presented.
  • Patients showed meaningful tumor shrinkage in a heavily pretreated setting, supporting continued development of the program.
  • Safety looked manageable, with immune-related reactions generally mild and concentrated early in treatment.
  • The FDA granted Fast Track designation for CTIM-76 in this ovarian cancer setting, strengthening the regulatory path.
  • The dosing strategy is set to shift toward less frequent administration in 2H 2026, with expansion decisions targeted for 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606150630PRIMZONEFULLFEED9746718) on June 15, 2026, and is solely responsible for the information contained therein.